[Translated article] Influence of age on the efficacy of immunochemotherapy in non-small cell lung cancer
Both those younger and older than 65 years benefit from immunotherapy combined with chemotherapy in the treatment of non-small cell lung cancer. Although there appears to be greater efficacy in those younger than 65 years, the influence of age is not entirely clear.
Authors
- Alicia Aguado-Paredes
- Jaime Ramos (ORCID: https://orcid.org/0000-0001-6223-3844)
- Laura Moñino-Dominguez
- Emilio Alegre-Del-Rey
Institutions
- Hospital Universitario Virgen Macarena (ES)
- Servicio Aragonés de Salud (ES)
- Hospital Universitario Puerto Real (ES)
Publication Details
- Journal
- Farmacia Hospitalaria
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1016/j.farma.2025.10.007
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00